Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013

[1] Vlieghe P., Lisowski, V., Martinez, J., Khrestchatisky, M., Synthetic therapeutic peptides: science and market, Drug Discovery Today., 2010, 15, 40-5610.1016/j.drudis.2009.10.00919879957Search in Google Scholar

[2] Lawrence S., Biotech blockbusters consolidate markets, Nat.Biotechnol., 2006, 24, 146610.1038/nbt1206-146617160033Search in Google Scholar

[3] Kohler M., Thomas, A., Geyer, H., Petrou, M., Schänzer, W., Thevis, M., Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory 2009, Drug Test Analysis., 2010, 2, 533-53710.1002/dta.18621204286Search in Google Scholar

[4] Jetté L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.et al., Human Growth Hormone-Releasing Factor (hGRF)1−29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog, Endocrinology., 2005, 146, 3052-305810.1210/en.2004-128615817669Search in Google Scholar

[5] Patient Died in Lipodystrophy Drug Study, http://www.natap.org/2006/newsUpdates/081106_02.htmSearch in Google Scholar

[6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, http://clinicaltrials.gov/ct2/show/NCT00267527Search in Google Scholar

[7] Thevis M., Loo, J. A., Loo, R. R. O., Schänzer, W., Recommended criteria for the mass spectrometric identification of target peptides and proteins (<kDa) in sports drug testing, Rapid Commun.Mass Spectrom., 2007, 21, 297-30410.1002/rcm.284817200979Search in Google Scholar

[8] Mallick P., Schirle, M., Chen, S. S., Flory, M. R., Lee, H., Martin, D.et al., Computational prediction of proteotypic peptides for quantitative proteomics, Nat.Biotechnol., 2007, 25, 125-13110.1038/nbt127517195840Search in Google Scholar

[9] Thomas A., Kohler, M., Mester, J., Geyer, H., Schanzer, W., Petrou, M.et al., Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement, Drug Test.Anal., 2010, 2, 144-14810.1002/dta.12020878896Search in Google Scholar

[10] Thomas A., Höppner, S., Geyer, H., Schänzer, W., Petrou, M., Kwiatkowska, D.et al., Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry, Anal Bioanal Chem., 2011, 401, 507-51610.1007/s00216-011-4702-321298258Search in Google Scholar

[11] Thevis M., Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays., 2010, 4910.1002/9780470626634Search in Google Scholar

[12] Henninge J., Pepaj, M., Hullstein, I., Hemmersbach, P., Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation, Drug Test Analysis., 2010, 2, 647-65010.1002/dta.23321204297Search in Google Scholar

[13] Mock S., Shen, X., Tamvakopoulos, C., Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration, Rapid Commun. Mass Spectrom., 2002, 16, 2142-214710.1002/rcm.847Search in Google Scholar

[14] Tamvakopoulos C., Mass spectrometry for the quantification of bioactive peptides in biological fluids, Mass Spectrom.Rev., 2007, 26, 389-40210.1002/mas.20120Search in Google Scholar

[15] Hatziieremia S., Kostomitsopoulos, N., Balafas, V., Tamvakopoulos, C., A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice, Rapid Commun.Mass Spectrom., 2007, 21, 2431-243810.1002/rcm.3106Search in Google Scholar

[16] Popot M. A., Woolfitt, A. R., Garcia, P., Tabet, J. C., Determination of IGF-I in horse plasma by LC electrospray ionisation mass spectrometry, Anal Bioanal Chem., 2008, 390, 1843-185210.1007/s00216-008-1889-zSearch in Google Scholar

[17] Kay R., Halsall, D. J., Annamalai, A. K., Kandasamy, N., Taylor, K., Fenwick, S.et al., A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly, Clin Endocrinol., 2013, 78, 424-43010.1111/cen.12085Search in Google Scholar

[18] Bredehöft M., Schänzer, W., Thevis, M., Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry, Rapid Commun. Mass Spectrom., 2008, 22, 477-48510.1002/rcm.3388Search in Google Scholar

[19] Thevis M., Bredehöft, M., Kohler, M., Schänzer, W., Mass Spectrometry-Based Analysis of IGF-1 and hGH., 2010, 195, 201-20710.1007/978-3-540-79088-4_9Search in Google Scholar

[20] Gam L. H., Tham, S. Y., Latiff, A., Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis, Journal of Chromatography B., 2003, 792, 187-19610.1016/S1570-0232(03)00264-2Search in Google Scholar

[21] Liu C. and Bowers, L. D., Mass spectrometric characterization of the beta-subunit of human chorionic gonadotropin, J.Mass Spectrom., 1997, 32, 33-4210.1002/(SICI)1096-9888(199701)32:1<33::AID-JMS446>3.0.CO;2-XSearch in Google Scholar

[22] Morten Bødskov., Forslag til lov om ændring af straffeloven., L 8, 2-10-2013, http://www.ft.dk/RIpdf/samling/20131/lovforslag/L8/20131_L8_som_vedtaget. pd Search in Google Scholar